Vividion Therapeutics racks up $135m Series C

Vividion Therapeutics, Inc., a biotechnology company, has secured $135 million in Series C financing.

24 February 2021•1 min read
Feature image
LinkedInXEmail
LinkedInXEmail

Related articles